{"id":29884,"date":"2019-12-18T16:50:13","date_gmt":"2019-12-18T16:50:13","guid":{"rendered":"http:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=29884"},"modified":"2019-12-18T16:50:13","modified_gmt":"2019-12-18T16:50:13","slug":"corey-cutler-ash-2019-evolving-treatment-for-patients-with-gvhd","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/haematology\/conference-hub\/corey-cutler-ash-2019-evolving-treatment-for-patients-with-gvhd\/","title":{"rendered":"Corey Cutler, ASH 2019: Evolving Treatment for Patients with GvHD"},"content":{"rendered":"<p>At the 61st ASH Annual Meeting &amp; Exposition, <strong>Corey Cutler<\/strong>, Dana Farber Cancer Institute, discusses his presentation: The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!<\/p>\n<p><strong>Questions<\/strong><\/p>\n<p>1. What are the major challenges in the treatment of patients with graft-versus-host disease (GvHD)? (0:05)<\/p>\n<p>2. How have recent advances in understanding of the biology of GvHD impacted on patient management? (0:45)<\/p>\n<p>3. What do you consider the most important emerging therapies for GvHD? (1:22)<\/p>\n<p>4. What do healthcare professionals need to know in terms of monitoring and appropriate management of treatment-related adverse events? (1:54)<\/p>\n<p>5. What other key messages of this symposium would you like to highlight? (2:33)<\/p>\n<p>&nbsp;<\/p>\n<p>Corey Cutler has no conflicts of interest to declare in relation to this video.<\/p>\n<p>Filmed at the 61st ASH Annual Meeting &amp; Exposition 2019, Orlando, FL, USA.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the 61st ASH Annual Meeting &amp; Exposition, Corey Cutler, Dana Farber Cancer Institute, discusses his presentation: The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes! Questions 1. What are the major challenges in the treatment of patients with graft-versus-host disease (GvHD)? (0:05) 2. How have recent advances in understanding [&hellip;]<\/p>\n","protected":false},"featured_media":29854,"template":"","class_list":["post-29884","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-haematology","video_categories-ash-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/29884"}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":0,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/29884\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/29854"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=29884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}